Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Plain-language summary
This trial is testing Cyclophosphamide for patients with adult T-cell leukemia/lymphoma (ATLL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. This trial is available at 19 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Biospecimen Collection (PROCEDURE): Undergo tissue and blood sample collection | Bone Marrow Biopsy (PROCEDURE): Undergo bone marrow biopsy | Computed Tomography (PROCEDURE): Undergo PET/CT or CT | Cyclophosphamide (DRUG): Given IV | Doxorubicin Hydrochloride (DRUG): Given IV | Echocardiography Test (PROCEDURE): Undergo ECHO | Etoposide (DRUG): Given IV | Lenalidomide (DRUG): Given PO | Multigated Acquisition Scan (PROCEDURE): Undergo MUGA | Positron Emission Tomography (PROCEDURE): Undergo PET/CT | Prednisone (DRUG): Given PO | Vincristine Sulfate (DRUG): Given IV
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide, Lenalidomide, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Vincristine Sulfate
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details